Avidity Biosciences Inc
RNAM
Pozycja w akcjach
#2070
Avidity Biosciences, Inc. is at the forefront of developing a novel class of... Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.
Cena akcji
$71.34
Ostatnia synchronizacja: 2026-03-03
Kapitalizacja rynkowa
$9.84B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
-
Kraj
US
Handel Avidity Biosciences Inc (RNAM)
Kategoria
Healthcare
Zyski dla Avidity Biosciences Inc (RNAM)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych Avidity Biosciences Inc, obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Avidity Biosciences Inc od 2018 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2025 | $-684.63M | 112.42% |
| 2024 | $-322.30M | 51.87% |
| 2023 | $-212.22M | 21.97% |
| 2022 | $-174.00M | 47.44% |
| 2021 | $-118.01M | 166.06% |
| 2020 | $-44.36M | 79.33% |
| 2019 | $-24.73M | 120.52% |
| 2018 | $-11.22M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $3.01B | - |
BE
|
|
| $1.95B | - |
NL
|
